Source comparison
CJC-1295 Without DAC vs With DAC: The Functional Distinction That Actually Matters
The only meaningful distinction in this category is not 'without' versus 'no'. It's whether or not the DAC modification is present. CJC-1295 with DAC (also called DAC:GRF) has a half-life of approximately five to seven days, allowing once- or twice-weekly dosi
This comparison does not assign a generated winner or score.
- The only meaningful distinction in this category is not 'without' versus 'no'. It's whether or not the DAC modification is present. CJC-1295 with DAC (also called DAC:GRF) has a half-life of approximately five to seven days, allowing once- or twice-weekly dosing. CJC-1295 without DAC (Mod GRF 1-29) has a half-life of roughly 30 minutes, requiring dosing timed to coincide with natural growth hormone pulse windows. Typically before sleep or around resistance training sessions. The pharmacokinetic difference is substantial: the DAC version produces sustained elevation of baseline growth hormone levels, while the non-DAC version amplifies existing pulses without altering baseline.
- This distinction matters in research contexts because the two peptides model different physiological scenarios. The DAC-modified version mimics continuous low-level GHRH stimulation. Similar to what would occur if the hypothalamus released GHRH steadily throughout the day. The non-DAC version mimics a single, sharp GHRH pulse. Matching the natural pattern where growth hormone is released in discrete bursts tied to circadian rhythm, sleep architecture, and metabolic state. Most researchers select the non-DAC version precisely because it preserves pulsatility, which is critical for downstream signaling pathways that depend on oscillating hormone levels rather than static elevation. Our experience at Real Peptides shows that laboratories studying circadian biology or metabolic pulsatility almost exclusively request the short-acting form.